The University of Chicago Header Logo

Connection

Hans Schreiber to Cytotoxicity, Immunologic

This is a "connection" page, showing publications Hans Schreiber has written about Cytotoxicity, Immunologic.
Connection Strength

0.436
  1. Unique tumor-specific antigens. Annu Rev Immunol. 1988; 6:465-83.
    View in: PubMed
    Score: 0.073
  2. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
    View in: PubMed
    Score: 0.071
  3. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47.
    View in: PubMed
    Score: 0.051
  4. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016 06 21; 44(6):1444-54.
    View in: PubMed
    Score: 0.033
  5. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 1996 May; 47(5):399-407.
    View in: PubMed
    Score: 0.033
  6. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A. 1995 Jul 03; 92(14):6254-8.
    View in: PubMed
    Score: 0.031
  7. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur J Immunol. 1993 Nov; 23(11):2770-6.
    View in: PubMed
    Score: 0.027
  8. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med. 1993 Sep 01; 178(3):933-40.
    View in: PubMed
    Score: 0.027
  9. Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors. Ann N Y Acad Sci. 1993 Aug 12; 690:244-55.
    View in: PubMed
    Score: 0.027
  10. Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. J Immunol. 2009 Aug 01; 183(3):1828-37.
    View in: PubMed
    Score: 0.020
  11. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med. 1989 Jul 01; 170(1):217-32.
    View in: PubMed
    Score: 0.020
  12. Relationship of tumour necrosis factor and endotoxin to macrophage cytotoxicity, haemorrhagic necrosis and lethal shock. Ciba Found Symp. 1987; 131:124-39.
    View in: PubMed
    Score: 0.017
  13. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A. 1990 Feb; 87(4):1486-90.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.